Received Aug 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 5Y4TL | — |
received a dose of Shingrix more than one year later from the first dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a adult female patient who received Herpes zoster (Shingrix) (batch number 5Y4TL, expiry date 31-JAN-2027) for prophylaxis. Previously administered products included Shingrix (received first dose in March 2024). On 14-AUG-2025, the patient received the 2nd dose of Shingrix. On 14-AUG-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: received a dose of Shingrix more than one year later from the first dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 14-AUG-2025 The patient received the second dose of Shingrix later than the recommended interval, which led to lengthening of vaccine schedule. The reporter asked that the patient need to restart the series.